These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 28123247)
41. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Baek SU; Park IW; Suh W Cutan Ocul Toxicol; 2016 Dec; 35(4):310-4. PubMed ID: 26820610 [TBL] [Abstract][Full Text] [Related]
42. Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. Seth RK; Salim S; Shields MB; Adelman RA Retina; 2009; 29(7):956-9. PubMed ID: 19584654 [TBL] [Abstract][Full Text] [Related]
43. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Knip MM; Välimäki J Acta Ophthalmol; 2012 May; 90(3):254-8. PubMed ID: 20456259 [TBL] [Abstract][Full Text] [Related]
44. The effect of intravitreal triamcinolone on intraocular pressure. Kramar M; Vu L; Whitson JT; He YG Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723 [TBL] [Abstract][Full Text] [Related]
45. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Benz MS; Albini TA; Holz ER; Lakhanpal RR; Westfall AC; Iyer MN; Carvounis PE Ophthalmology; 2006 Jul; 113(7):1174-8. PubMed ID: 16647122 [TBL] [Abstract][Full Text] [Related]
46. Observation of total VEGF level in hyperglycemic mouse eyes after intravitreal injection of the novel anti-VEGF drug conbercept. Du L; Peng H; Wu Q; Zhu M; Luo D; Ke X; Yang P; Lei B Mol Vis; 2015; 21():185-93. PubMed ID: 25737631 [TBL] [Abstract][Full Text] [Related]
47. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections. Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262 [TBL] [Abstract][Full Text] [Related]
48. [Late and sustained intraocular pressure elevation related to intravitreal anti-VEGF injections: Cases requiring filtering surgery (French translation of the article)]. Leleu I; Penaud B; Blumen-Ohana E; Rodallec T; Adam R; Laplace O; Akesbi J; Nordmann JP J Fr Ophtalmol; 2018 Nov; 41(9):789-801. PubMed ID: 30348599 [TBL] [Abstract][Full Text] [Related]
49. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting. Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613 [TBL] [Abstract][Full Text] [Related]
50. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465 [TBL] [Abstract][Full Text] [Related]
51. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Moraczewski AL; Lee RK; Palmberg PF; Rosenfeld PJ; Feuer WJ Br J Ophthalmol; 2009 May; 93(5):589-93. PubMed ID: 19074917 [TBL] [Abstract][Full Text] [Related]
52. Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity. Gao C; Mu G; Zhao H; Zheng J; Feng Q; Wu Y; Li Y; Huang X; Sun W Front Pharmacol; 2023; 14():1165356. PubMed ID: 37324456 [No Abstract] [Full Text] [Related]
53. Efficacy and safety of intravitreal drug injections using a short 34-gauge needle. Sasajima H; Tsuboi K; Murotani K; Kamei M Jpn J Ophthalmol; 2019 May; 63(3):269-275. PubMed ID: 30955120 [TBL] [Abstract][Full Text] [Related]
54. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353 [TBL] [Abstract][Full Text] [Related]
55. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Frenkel MP; Haji SA; Frenkel RE Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773 [TBL] [Abstract][Full Text] [Related]
56. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Kotliar K; Maier M; Bauer S; Feucht N; Lohmann C; Lanzl I Acta Ophthalmol Scand; 2007 Nov; 85(7):777-81. PubMed ID: 17573861 [TBL] [Abstract][Full Text] [Related]
57. [Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection]. Dwinger MC; Pieper-Bodeewes I; Eter N; Holz FG Klin Monbl Augenheilkd; 2005 Aug; 222(8):638-42. PubMed ID: 16118744 [TBL] [Abstract][Full Text] [Related]
58. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study. Song S; Yu XB; Dai H Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340 [TBL] [Abstract][Full Text] [Related]
59. A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration. Matsubara H; Miyata R; Kobayashi M; Tsukitome H; Ikesugi K; Kondo M Case Rep Ophthalmol; 2016; 7(1):230-6. PubMed ID: 27462248 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of short-term intraocular pressure changes after intravitreal injection of Conbercept in patients with diabetic macular edema. Hu Y; Zeng Y; Yang J; Zeng X; Cao D; Ou B; Zhang G; Zhang L Front Pharmacol; 2022; 13():1025205. PubMed ID: 36578537 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]